Toggle light / dark theme

After a much-anticipated GAO denial of Blue Origin and Dynetics protests over NASA’s decision to solely award SpaceX a contract to turn Starship into a crewed Moon lander, an in-depth (but heavily redacted) document explaining that decision was released on August 10th.

Aside from ruthlessly tearing both companies’ protests limb from limb, the US Government Accountability Office’s decision also offered a surprising amount of insight into SpaceX’s HLS Starship proposal. One of those details in particular seemed to strike an irrational nerve in the online spaceflight community. Specifically, in its decision, GAO happened to reveal that SpaceX had proposed a mission profile that would require as many as 16 launches to fully fuel a Starship Lander and stage the spacecraft in an unusual lunar orbit.

After around 24 hours of chaos, confusion, and misplaced panic, SpaceX CEO Elon Musk finally weighed in on the GAO document’s moderately surprising indication that each Starship Moon landing would require sixteen SpaceX launches.

Heat flows naturally through the TEG because its cold side is kept at room temperature, while its hot side, which is in thermal contact with the cell, is at a high temperature. The Seebeck effect, which is the direct conversion of temperature differences between two semiconductor materials into electric voltage, generates this difference which then translates into additional electrical power.

The scientists decided not to use a spectrum splitting technology, which is generally utilized in these applications, to direct different parts of the solar spectrum towards either the PV or the TEG unit. “It is more convenient, in terms of final efficiency gains, to keep the solar cell at the same temperature of the TEG hot side, instead of keeping the cell cold but losing much of the recoverable heat,” the academics explained, noting that a wide-gap solar cell based on perovskite was chosen for the device, due to its lower sensitivity to high temperatures. “Temperature-sensitive materials, such as silicon, lose too much efficiency to make the hybridization convenient,” they further explained.

Researchers at the Stanford Institute for Stem Cell Biology and Regenerative Medicine have discovered how changes in aging skeletal stem cells may be an underlying cause of poor fracture healing, osteoporosis and various blood disorders as well as generalized inflammation and aging (sometimes called “inflamm-aging”) of cells and systems throughout the body. However, the researchers are also discovering how they might reinvigorate aging skeletal stem cell so that they start acting younger again, potentially reversing these changes.

“Skeletal stem give rise to bone, cartilage, and special cells that provide a niche or nursery for blood and to develop,” said Charles Chan, PhD, a member of the institute and an assistant professor in the Department of Surgery, Plastic and Reconstructive Surgery, and Immunology. “So if aged skeletal stem cells are not performing well, they can contribute to a wide variety of the disorders that we find in older people.”

The Research was published in the journal Nature. Chan and professor Michael Longaker, MD, are senior authors on the paper. Longaker is the Dean P. and Louise Mitchell Professor in the School of Medicine and a member of the Institute for Stem Cell Biology and Regenerative Medicine. Postdoctoral fellow Thomas Ambrosi, PhD is a co-first author along with former medical student Owen Marecic, MD and former postdoctoral fellow Adrian McArdle, MD, PhD.

Hematopoietic stem cells—the precursors to blood cells—have been notoriously difficult to grow in a dish, a critical tool in basic research. Scientists at University of California San Diego School of Medicine have identified the underlying issue and developed a method to keep cultured cells healthy. These findings, they say, are positive news for patients seeking stem cell transplants—and may hint at a new way to ward off aging.

The findings will be published in the August 12 2021 online issue of Cell Stem Cell.

In transplants, hematopoietic stem are infused intravenously to reestablish blood production in patients whose bone marrow or is damaged. The procedure is used to treat diseases such as leukemia, lymphoma, aplastic anemia and immune deficiency disorders. However, are not always available for patients who need them.

Steroid-based inhalers deliver life-saving medication for millions of asthma sufferers, providing relief and the ability to simply breathe. Unfortunately, inhalers do not work for all patients, and with rates on the rise for a disease that leads to hundreds of thousands of deaths world-wide each year, new asthma treatments and strategies are needed.

A team of UConn researchers—including Assistant Professor of Chemistry in the College of Liberal Arts and Sciences Jessica Rouge and Associate Professor of Pathobiology in the College of Agriculture, Health, and Natural Resources Steven Szczepanek—are collaborating to develop novel therapeutics using gene-silencing nanocapsules in a bid to help patients who aren’t benefiting from existing treatments. Their research was published in ACS Nano.

“When treating asthma, many people think of small molecule anti-inflammatory medications as the way to go, but there are plenty of patients who have asthma who do not respond to corticosteroids,” says Rouge. “There’s an unmet need for creating different therapeutics that can suppress asthma for this group of people.”

A 21st Century Mystery School — “Creating New Paradigms In Wellness And Wisdom Never Seen Before, And Never More Needed Than Now” — Dr. Dennis McKenna, Founder, McKenna Academy of Natural Philosophy.


Dr. Dennis McKenna is an American ethnopharmacologist, research pharmacognosist, lecturer, author, and Founder of the McKenna Academy of Natural Philosophy (www.mckenna.academy).

Dr. McKenna is a founding board member and the director of ethnopharmacology at the Heffter Research Institute, a non-profit organization concerned with the investigation of the potential therapeutic uses of psychedelic medicines. He also serves on the Advisory Board of the American Botanical Council; as Founder and Executive Director for the Institute for Natural Products Research; as an Independent Research Consultant to the Phytomedicine and Nutraceutical Industry; was formerly on the Editorial Board of Phytomedicine, International Journal of Phytotherapy and Phytopharmacology; and is an adjunct professor in the Center for Spirituality and Healing at the University of Minnesota.